Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Wanner

Showing results (311-320 of 785) with videos related to

Pageof 79
Sort By:
Plos One|May 22, 2013
Homoarginine and progression of chronic kidney disease: results from the Mild to Moderate Kidney Disease StudyChristiane Drechsler, Barbara Kollerits, Andreas Meinitzer, et al.
Cardiovascular Diabetology|April 1, 2021
Report from the CVOT Summit 2020: new cardiovascular and renal outcomesOliver Schnell, Xavier Cos, Francesco Cosentino, et al.
Journal of Inherited Metabolic Disease|October 12, 2012
Cross-sectional baseline analysis of electrocardiography in a large cohort of patients with untreated Fabry diseaseMarkus Niemann, Tanja Hartmann, Mehdi Namdar, et al.
European Heart Journal Open|April 20, 2026
Intraepidermal nerve fiber density as a predictor of cardiac events in Fabry diseaseKolja Lau, Dan Liu, Victoria Sokalski, et al.
The Journal of Clinical Endocrinology and Metabolism|June 3, 2020
Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME TrialSilvio E Inzucchi, Kamlesh Khunti, David H Fitchett, et al.
Kidney International|December 11, 2002
Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation?Martin Zeier, Vedat Schwenger, Reinhold Deppisch, et al.
Nephron. Clinical Practice|November 8, 2014
Longitudinal assessments of erythropoietin-stimulating agent responsiveness and the association with specific clinical outcomes in dialysis patientsAndreas Schneider, Lena Gutjahr-Lengsfeld, Eberhard Ritz, et al.
The American Journal of Cardiology|May 9, 2006
Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathyMeinrad Beer, Frank Weidemann, Frank Breunig, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|May 28, 2013
Increased symmetrical dimethylarginine in ischemic acute kidney injury as a causative factor of renal L-arginine deficiencyBoris Betz, Kerstin Möller-Ehrlich, Tobias Kress, et al.
Molecular Genetics and Metabolism|January 29, 2023
Patient reported quality of life and medication adherence in Fabry disease patients treated with migalastat: A prospective, multicenter studyJonas Müntze, Kolja Lau, Markus Cybulla, et al.
Pageof 79

Showing results (311-320 of 785) with videos related to

Sort By:
Pageof 79
Plos One|May 22, 2013
Homoarginine and progression of chronic kidney disease: results from the Mild to Moderate Kidney Disease StudyChristiane Drechsler, Barbara Kollerits, Andreas Meinitzer, et al.
Cardiovascular Diabetology|April 1, 2021
Report from the CVOT Summit 2020: new cardiovascular and renal outcomesOliver Schnell, Xavier Cos, Francesco Cosentino, et al.
Journal of Inherited Metabolic Disease|October 12, 2012
Cross-sectional baseline analysis of electrocardiography in a large cohort of patients with untreated Fabry diseaseMarkus Niemann, Tanja Hartmann, Mehdi Namdar, et al.
European Heart Journal Open|April 20, 2026
Intraepidermal nerve fiber density as a predictor of cardiac events in Fabry diseaseKolja Lau, Dan Liu, Victoria Sokalski, et al.
The Journal of Clinical Endocrinology and Metabolism|June 3, 2020
Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME TrialSilvio E Inzucchi, Kamlesh Khunti, David H Fitchett, et al.
Kidney International|December 11, 2002
Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation?Martin Zeier, Vedat Schwenger, Reinhold Deppisch, et al.
Nephron. Clinical Practice|November 8, 2014
Longitudinal assessments of erythropoietin-stimulating agent responsiveness and the association with specific clinical outcomes in dialysis patientsAndreas Schneider, Lena Gutjahr-Lengsfeld, Eberhard Ritz, et al.
The American Journal of Cardiology|May 9, 2006
Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathyMeinrad Beer, Frank Weidemann, Frank Breunig, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|May 28, 2013
Increased symmetrical dimethylarginine in ischemic acute kidney injury as a causative factor of renal L-arginine deficiencyBoris Betz, Kerstin Möller-Ehrlich, Tobias Kress, et al.
Molecular Genetics and Metabolism|January 29, 2023
Patient reported quality of life and medication adherence in Fabry disease patients treated with migalastat: A prospective, multicenter studyJonas Müntze, Kolja Lau, Markus Cybulla, et al.
Pageof 79